Trial ID or NCT#





Primary Objectives: 1. To investigate the response rate (complete response plus partial response) of temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the central nervous system (mass only) in two strata: - A. Initial diagnosis (mass) - B. At relapse (mass) 2. To determine hematologic toxicity: absolute neutrophil count (ANC), platelets and hemoglobin count. Secondary Objectives: 1. To determine the response in other metastatic sites (non target) (orbit, bone marrow, bone, lung, liver and others) 2. To determine the remission rate and time to relapse on temozolomide. 3. To document the response of leptomeningeal metastasis (cerebrospinal fluid) to temozolomide

Official Title

Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Contact us to find out if this trial is right for you.


Mauricio Castellanos, MD